Key Highlights
- Evogene (EVGN) is using its ChemPass AI platform with ELEO to design oral PCSK9 inhibitors for a market projected above $23 billion by 2035.
- The company is pre-profit with roughly $13.1 million cash, falling revenue and repeated dilutive financings.
- EVGN traded near $0.52 in late July 2026, below Nasdaq's $1.00 minimum, raising delisting and reverse-split risk.
- The risks here are substantial and structural, typical of a cash-constrained micro-cap.
Why Evogene Is in Focus
Evogene Ltd. (NASDAQ:EVGN), an Israeli computational biology company, is betting that generative AI can crack one of cardiology's harder problems: a cholesterol pill that rivals injectable blockbusters. At last closing, EVGN unveiled a collaboration with South Korea's ELEO Inc. to discover oral small-molecule PCSK9 pathway inhibitors. It is the latest in a string of pharma-discovery deals as Evogene pivots its AI engines toward drug design. For a company valued at roughly $6 million, the ambition is outsized, and so are the risks. That gulf between a multibillion-dollar opportunity and a valuation of a few million dollars is precisely what makes the stock read as a lottery ticket rather than a conventional bet.
What has happened?
Under the July 22 agreement, Evogene will deploy its ChemPass AI platform to design, optimize and prioritize novel small molecules targeting PCSK9, focusing on oral potency, bioavailability, selectivity and drug-like properties. ELEO contributes biological expertise: target validation, PCSK9 suppression models and screening platforms to test the computationally designed candidates. No financial terms were disclosed. The two companies said they will explore strategic options, including clinical development pathways and licensing partnerships with larger pharmaceutical firms. The deal follows three other pharma collaborations Evogene disclosed in the first quarter of 2026, with Systasy Biosciences/LMU Munich, Queensland University of Technology and Unravel Biosciences, signaling a broad push to license its discovery platform rather than develop drugs alone.
Why the development matters
PCSK9 inhibitors lower LDL cholesterol powerfully, but approved therapies such as the leading monoclonal antibodies are injectables, expensive and, for many patients, inconvenient. An effective oral small molecule could expand access dramatically. Evogene and ELEO cite a market projected to grow from about $4.4 billion in 2025 to over $23 billion by 2035. For EVGN, success would validate ChemPass AI as a revenue-generating discovery engine and could attract milestone-and-royalty deals with global drugmakers. That is the bull case. The sober reality is that this is very early-stage discovery, years from any clinic, with no economics attached yet. In effect, investors are being asked to price the optionality of a platform rather than the value of a product, which helps explain why the potential reward and the probability of failure loom equally large in this story.
Company and business overview
Evogene, founded in 2002 and listed on both Nasdaq and the Tel Aviv Stock Exchange, built its reputation in computational biology for agriculture. Its core technology engines, GeneRator AI, MicroBoost AI and ChemPass AI, are now being redirected toward pharmaceutical and other applications. The company has spent recent quarters restructuring its subsidiaries. Lavie Bio's operations were discontinued by the end of Q1 2026; Biomica licensed its lead oncology candidate BMC128 to Lishan Pharmaceuticals; and seed unit Casterra scaled back to focus on Brazil ahead of planned 2027 sales. AgPlenus ended its herbicide collaboration with Bayer while advancing an internal fungicide program. The pharma-discovery pivot, anchored by ChemPass AI, is increasingly the company's headline story.
Financial position and funding runway
Evogene is pre-profit and heavily dependent on external funding. It held roughly $13.1 million in consolidated cash, cash equivalents and short-term deposits, and consumed about $2.8 million during the quarter. First-quarter 2026 revenue fell to about $0.3 million from $2.3 million a year earlier, largely reflecting lower Casterra seed sales, while the net loss widened to roughly $5.9 million from $3.0 million. The company has repeatedly tapped capital markets, including an at-the-market program, a warrant inducement and registered direct offerings.
Expected subsidiary dividends, Evogene's share of about $2.9 million from Lavie Bio and roughly $1.35 million from Biomica in Q2 2026, offer modest near-term cash relief. Even so, a quarterly burn of about $2.8 million set against roughly $13.1 million in cash implies a runway measured in quarters rather than years, which underscores why repeated trips to the capital markets have become a routine feature of the model rather than an occasional necessity.
Potential growth catalysts
Evogene's upside hinges on turning AI platforms into paying partnerships and validated discovery milestones.
- Progress in the ELEO PCSK9 program, particularly identification of viable oral small-molecule leads.
- New pharma collaborations building on the four disclosed by mid-2026, potentially with larger, better-capitalized partners.
- A February 2026 ChemPass AI collaboration with Google Cloud to integrate advanced AI agents, which could sharpen the platform's capabilities.
- Milestone or licensing payments that would diversify revenue away from volatile agricultural seed sales.
- Cash inflows from approved subsidiary dividends expected in the second quarter of 2026.
Principal risks investors should understand
The risks here are substantial and structural, typical of a cash-constrained micro-cap.
- Dilution: Evogene has funded itself through repeated equity raises, ATM sales and warrant deals, pressuring existing shareholders.
- Going-concern and runway risk: with roughly $13.1 million in cash and ongoing losses, funding beyond the near term is uncertain.
- Delisting risk: EVGN traded near $0.52 in late July 2026, below Nasdaq's $1.00 minimum bid threshold, raising the prospect of a reverse split or compliance action.
- Execution risk: AI-designed drug discovery is unproven at scale, and the ELEO program is pre-clinical with no disclosed economics.
- Revenue concentration and decline: total revenue has fallen sharply as legacy agricultural units wind down.
What to monitor next
Investors should track the milestones that would separate promise from progress.
- Any data or lead-candidate updates from the ELEO PCSK9 collaboration.
- Cash balance, quarterly burn and any new financing announcements or their terms.
- Nasdaq listing compliance and any reverse-split notices.
- Additional platform partnerships or upfront/milestone payments that generate real revenue.
- Execution on the Google Cloud ChemPass AI integration and subsidiary restructuring outcomes.
Conclusion
EVGN offers a high-risk, high-optionality story: a tiny company applying generative AI to a large, unmet cardiovascular need. The ELEO partnership is genuinely intriguing and taps a market that could exceed $23 billion, yet it remains discovery-stage with no disclosed financials and a long road to any clinic. Meanwhile, Evogene must manage thin cash, shrinking legacy revenue, dilution and a share price below Nasdaq's minimum. For investors, EVGN is best understood as a speculative wager on platform validation, not proven earnings. Watch the cash and the science in equal measure.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...